<code id='28417BE499'></code><style id='28417BE499'></style>
      • <acronym id='28417BE499'></acronym>
      <center id='28417BE499'><center id='28417BE499'><tfoot id='28417BE499'></tfoot></center><abbr id='28417BE499'><dir id='28417BE499'><tfoot id='28417BE499'></tfoot><noframes id='28417BE499'>
      • <optgroup id='28417BE499'><strike id='28417BE499'><sup id='28417BE499'></sup></strike><code id='28417BE499'></code></optgroup>
        5. <b id='28417BE499'><label id='28417BE499'><select id='28417BE499'><dt id='28417BE499'><span id='28417BE499'></span></dt></select></label></b><u id='28417BE499'></u>
          <i id='28417BE499'><strike id='28417BE499'><tt id='28417BE499'><pre id='28417BE499'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / explore / explore      
           
     
           
      
          explore 
           
      
           
      
           
       2025-10-02 05:06:44 
   
      
           
      
           
                        
          explore  
          
                                   
                 
                                      author：focus   
                                        
                                      
                                      Page View：39
                                  
                                    
          
                                   
          Franklin faces
          Adobe
          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.
          advertisement
          Arch declined to comment on the new fundraising.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          JPM 2024: Verve Therapeutics looks to mainstream genome editing
                                
                            
          Next article：  
                                      
                                          New air purifier tech could be key to improving indoor air quality
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles